Mabwell (Shanghai) Bioscience Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Mabwell (Shanghai) Bioscience kazanç ve gelirin sırasıyla yıllık 58.2% ve 87.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 58.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -24.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

58.2%

Kazanç büyüme oranı

58.3%

EPS büyüme oranı

Biotechs kazanç büyümesi	43.4%
Gelir büyüme oranı	87.8%
Gelecekteki özkaynak getirisi	-24.1%
Analist kapsamı	Low
Son güncelleme	13 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Mabwell (Shanghai) Bioscience (SHSE:688062) Has Debt But No Earnings; Should You Worry?

Aug 19

Kazanç ve Gelir Büyüme Tahminleri

SHSE:688062 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	1,779	-138	-29	43	5
12/31/2025	961	-609	-528	-374	5
12/31/2024	326	-903	-789	-966	5
9/30/2024	169	-1,074	-1,153	-888	N/A
6/30/2024	153	-1,085	-1,209	-923	N/A
3/31/2024	191	-1,018	-1,349	-961	N/A
12/31/2023	128	-1,053	-1,283	-783	N/A
9/30/2023	107	-936	-1,375	-774	N/A
6/30/2023	107	-945	-1,479	-777	N/A
3/31/2023	28	-976	-1,271	-611	N/A
12/31/2022	28	-955	-1,264	-719	N/A
9/30/2022	26	-947	-1,148	-657	N/A
6/30/2022	20	-853	-932	-550	N/A
3/31/2022	20	-833	-858	-578	N/A
12/31/2021	16	-770	-640	-422	N/A
9/30/2021	11	-699	-581	-392	N/A
12/31/2020	5	-643	-646	-515	N/A
12/31/2019	29	-928	-540	-354	N/A
12/31/2018	37	-225	-380	-156	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 688062 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 688062 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 688062 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 688062 şirketinin gelirinin (yıllık 87.8% ) CN pazarından (yıllık 13.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 688062 şirketinin gelirinin (yıllık 87.8% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 688062 3 yıl içinde kârsız olması bekleniyor.

Mabwell (Shanghai) Bioscience Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 8.5% to CN¥35.92

Recent updates

Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA

New major risk - Share price stability

Mabwell (Shanghai) Bioscience Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer

Mabwell (Shanghai) Bioscience (SHSE:688062) Has Debt But No Earnings; Should You Worry?

Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's NMPA

New minor risk - Share price stability

FDA Grants Orphan Drug Designation to 7MW3711

FDA Grants Fast Track Designation to Mabwell's 9MW2821 for the Treatment of Patients with Locally Advanced or Metastatic Nectin-4 Positive TNBC

Mabwell (Shanghai) Bioscience Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Mabwell Announces 9MW2821 Clinical Data

Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer

Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821

First quarter 2024 earnings released: CN¥0.51 loss per share (vs CN¥0.60 loss in 1Q 2023)

Price target increased by 8.5% to CN¥35.92

Full year 2023 earnings: EPS and revenues miss analyst expectations

Mabwell (Shanghai) Bioscience Co., Ltd., Annual General Meeting, Apr 29, 2024

Mabwell (Shanghai) Bioscience Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Mabwell Presents Clinical Study Data of the 9MW2821 for Patients with Cervical Cancer as Focused Plenary Oral Presentation At the Society of Gynecologic Oncology Annual Meeting

Mabwell Publishes Phase III Study Results of Denosumab Biosimilar in the International Top Journal of Jama Oncology

Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7Mw3711

Mabwell (Shanghai) Bioscience Co., Ltd. to Report Fiscal Year 2023 Results on Apr 09, 2024

National Medical Products Administration Accepts Mabwell's 8MW0511 for Injection Accepted by NMPA

Mabwell Announces the Cde Approval of Novel Nectin-4 Targeting Adc for Phase III Clinical Trial

Insufficient new directors

New major risk - Financial position

Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs

Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor

New major risk - Financial position

Second quarter 2023 earnings released: CN¥0.43 loss per share (vs CN¥0.51 loss in 2Q 2022)

Mabwell (Shanghai) Bioscience Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Mabwell (Shanghai) Bioscience Co., Ltd. Announces the U.S. FDA approval of 9MW3811 for IND

Full year 2022 earnings released: CN¥2.44 loss per share (vs CN¥2.57 loss in FY 2021)

Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND

High number of new and inexperienced directors

Third quarter 2022 earnings released: CN¥0.67 loss per share (vs CN¥0.58 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.51 loss per share (vs CN¥0.58 loss in 2Q 2021)

First quarter 2022 earnings released: CN¥0.55 loss per share (vs CN¥0.61 loss in 1Q 2021)

Full year 2021 earnings released: CN¥2.57 loss per share (vs CN¥2.26 loss in FY 2020)

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin